gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Taming of the shrew retinoblastomas

Meeting Abstract

  • Markus Holdt - Universitäts-Augenklinik Essen
  • E. Biewald - Universitäts-Augenklinik Essen
  • S. Göricke - Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, UK Essen
  • M. Schündeln - Klinik für Kinderheilkunde III, UK Essen
  • W. Sauerwein - Klinik für Strahlentherapie, UK Essen
  • N. Bornfeld - Universitäts-Augenklinik Essen

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg23

doi: 10.3205/11rg23, urn:nbn:de:0183-11rg232

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2011/11rg23.shtml

Published: June 15, 2011

© 2011 Holdt et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

A 18 month old boy with bilateral sporadic retinoblastoma (right > left) received according international recommendations a systemic intravenous polychemotherapy with 6 cycles each 3 weeks, 4 cycles with thermotherapy. 3 months after finishing chemotherapy relapses on both eyes occurred. We treated with external beam radiotherapy of both eyes up to 50 Gray about 5 weeks. 6 months after finishing radiotherapy a relapse on the better left eye occurred. Superselective intraarterial chemotherapy failed because of a strong anastomosis between ophthalmic and meningeal artery. We treated with intravitreal methotrexate-injections 2x weekly about 4 weeks and 1x weekly about further 4 weeks. The righte eye developed a relapse around 11 months after radiotherapy. Superselective intraarterial chemotherapy with 5 mg Melphalan succeeded on the right eye. To date both eyes are showing inactive tumours. Following examinations under anaesthesia are necessary. MRI-imaging showed no extraocular growth, but an atypical enhancement of the left optic nerve. Recurrent retinoblastoma are presenting a special challenge. Therapeutical options are combined with known potential complications. Recent additonal therapeutical options are demonstrating relevant successes but also compromises.